Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

By Antoni Ribas, R. Kefford, M. Marshall, C. Punt, J. Haanen, M. Mármol, C. Garbe, H. Gogas, J. Schachter, G. Linette and 14 more. Journal of Clinical Oncology, 2013

719 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/6aa3577e01b97ff1101387fb9240e5d5793d9f4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Immune Checkpoint Blockade in Cancer Therapy. (2015, background): “III study comparing tremelimumab to dacarbazine/ temozolomide inpatientswithadvancedmelanoma.(13)”
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells (2013, background): “Tremelimumab, which—like ipilimumab— inhibits CTLA-4-B7 interactions, has demonstrable antitumor activity in metastatic melanoma (40, 41).”
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016, neutral): “[2,51,67,68], anti-PD-1 [3,11,19,33,59,69,70] or anti-PD-L1”
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2015, background): “Anti-CTLA4 mAbs are associated with elevated AST and ALT levels in 10% of patients or less [20, 21, 54, 69].”
Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, background): “Although tremelimumab, a distinct CTLA-4-blocking mAb, showed promise in early-phase melanoma trials, it did not meet its designated endpoint when randomized against standard chemotherapy in a first-line phase III melanoma trial (Ribas et al., 2013).”